Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality Insights From the EMPA-REG OUTCOME Trial

被引：49

作者：

Savarese, Gianluigi ^{[1
]}

Sattar, Naveed ^{[2
]}

Januzzi, James ^{[3
,4
]}

Verma, Subodh ^{[5
]}

Lund, Lars H. ^{[1
]}

Fitchett, David ^{[6
]}

Zeller, Cordula ^{[8
]}

George, Jyothis T. ^{[9
]}

Brueckmann, Martina ^{[9
,10
]}

Ofstad, Anne Pernille ^{[11
]}

Inzucchi, Silvio E. ^{[12
]}

Wanner, Christoph ^{[13
]}

Zinman, Bernard ^{[7
]}

Butler, Javed ^{[14
]}

机构：

[1] Karolinska Inst, Dept Med, Cardiol Unit, Stockholm, Sweden

[2] Univ Glasgow, Glasgow, Lanark, Scotland

[3] Massachusetts Gen Hosp, Cardiol Div, Boston, MA 02114 USA

[4] Baim Inst Clin Res, Boston, MA 02114 USA

[5] St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Cardiac Surg, Toronto, ON, Canada

[6] St Michaels Hosp, Div Cardiol, Toronto, ON, Canada

[7] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada

[8] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[9] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[10] Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany

[11] Boehringer Ingelheim Norway KS, Asker, Norway

[12] Yale Univ, Yale New Haven Hosp, Sch Med, Sect Endocrinol, New Haven, CT USA

[13] Univ Hosp Wurzburg, Dept Internal Med 1, Nephrol, Wurzburg, Germany

[14] Univ Mississippi, Dept Med, Jackson, MS 39216 USA

来源：

CIRCULATION | 2019年 / 139卷 / 11期

关键词：

heart failure; hospitalization; mortality;

D O I：

10.1161/CIRCULATIONAHA.118.038339

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1458 / 1460

页数：3

共 5 条

[1] Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI [10.1161/CIR.0000000000000485, 10.1161/CIR.0000000000000558, 10.1161/CIR.0000000000000530]
[2] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
Fitchett, David
Zinman, Bernard
Wanner, Christoph
Lachin, John M.
Hantel, Stefan
Salsali, Afshin
Johansen, Odd Erik
Woerle, Hans J.
Broedl, Uli C.
Inzucchi, Silvio E.
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
[J]. EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
[3] Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure
Solomon, Scott D.
Dobson, Joanna
Pocock, Stuart
Skali, Hicham
McMurray, John J. V.
Granger, Christopher B.
Yusuf, Salim
Swedberg, Karl
Young, James B.
Michelson, Eric L.
Pfeffer, Marc A.
[J]. CIRCULATION, 2007, 116 (13) : 1482 - 1487
[4] SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, Subodh
McMurray, John J. V.
[J]. DIABETOLOGIA, 2018, 61 (10) : 2108 - 2117
[5] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, Bernard
Wanner, Christoph
Lachin, John M.
Fitchett, David
Bluhmki, Erich
Hantel, Stefan
Mattheus, Michaela
Devins, Theresa
Johansen, Odd Erik
Woerle, Hans J.
Broedl, Uli C.
Inzucchi, Silvio E.
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) : 2117 - 2128

← 1 →